Literature DB >> 24969952

[Antidepressive agents and suicidal tendencies].

G Gründer1, T Veselinović, M Paulzen.   

Abstract

In the last 2 years the discussions on the question whether antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) can lead to suicidality, aggression and violence, flared up again. The available data on the problem, which has been discussed since the introduction of this substance group in the late 1980s, is presented in this article. A systematic literature search showed that a scientific consensus exists that the benefits of antidepressant pharmacotherapy in general, and of treatment with SSRIs and selective serotonin/norepinephrine reuptake inhibitors (SSNRIs) in particular, outweigh the risks of their use. This also applies to the treatment of children, adolescents and young adults. The agitation occasionally occurring at the beginning of treatment, which can be experienced as aversive in susceptible patients, can intensify or even trigger suicidal thoughts or impulses. This has to be paid particular attention to especially at the beginning of treatment. It is recommended that the indications for antidepressant pharmacotherapy of children, adolescents and young adults are assessed by a specialist.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24969952     DOI: 10.1007/s00115-014-4092-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Suicide prevention--a medical breakthrough?

Authors:  G Isacsson
Journal:  Acta Psychiatr Scand       Date:  2000-08       Impact factor: 6.392

2.  Suicidal ideation not associated with fluoxetine.

Authors:  C E Hoover
Journal:  Am J Psychiatry       Date:  1991-04       Impact factor: 18.112

3.  Antidepressant medication and suicide in Sweden.

Authors:  A Carlsten; M Waern; A Ekedahl; J Ranstam
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

Review 4.  ACNP Task Force report on SSRIs and suicidal behavior in youth.

Authors:  J John Mann; Graham Emslie; Ross J Baldessarini; William Beardslee; Jan A Fawcett; Frederick K Goodwin; Andrew C Leon; Herbert Y Meltzer; Neal D Ryan; David Shaffer; Karen D Wagner
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

5.  Secular trends in antidepressant prescribing in the UK, 1975-1998.

Authors:  N Middleton; D Gunnell; E Whitley; D Dorling; S Frankel
Journal:  J Public Health Med       Date:  2001-12

6.  Persisting decline in depression treatment after FDA warnings.

Authors:  Anne M Libby; Heather D Orton; Robert J Valuck
Journal:  Arch Gen Psychiatry       Date:  2009-06

Review 7.  Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.

Authors:  Sitra Tauscher-Wisniewski; Mary Nilsson; Cathy Caldwell; John Plewes; Albert J Allen
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-10       Impact factor: 2.576

8.  Depression in adolescence.

Authors:  Anita Thapar; Stephan Collishaw; Daniel S Pine; Ajay K Thapar
Journal:  Lancet       Date:  2012-02-02       Impact factor: 79.321

9.  Antidepressants and lethal violence in the Netherlands 1994-2008.

Authors:  Paul F Bouvy; Marieke Liem
Journal:  Psychopharmacology (Berl)       Date:  2012-03-07       Impact factor: 4.530

Review 10.  Newer generation antidepressants for depressive disorders in children and adolescents.

Authors:  Sarah E Hetrick; Joanne E McKenzie; Georgina R Cox; Magenta B Simmons; Sally N Merry
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more
  2 in total

Review 1.  [Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention].

Authors:  R Haußmann; M Bauer; U Lewitzka; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 2.  Mechanisms of Panax ginseng action as an antidepressant.

Authors:  Yang Jin; Ranji Cui; Lihong Zhao; Jie Fan; Bingjin Li
Journal:  Cell Prolif       Date:  2019-10-10       Impact factor: 6.831

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.